April 30, 2021

IBRI RESEARCH PUBLISHED: The role of mediobasal hypothalamic PACAP in the control of body weight and metabolism

Abstract Body energy homeostasis results from balancing energy intake and energy expenditure. Central nervous system administration of pituitary adenylate cyclase activating polypeptide (PACAP) dramatically alters metabolic function, but the...

April 05, 2021

IBRI RESEARCH PUBLISHED: Multiplexed Signal Ion Emission Reactive Release Amplification Assay for the Culture-Free Detection of Gram-Negative, Gram-Positive Bacteria and Antimicrobial Resistance Genes

Abstract The global prevalence of antibiotic-resistant bacteria has increased the risk of dangerous infections, requiring rapid diagnosis and treatment. The standard method for diagnosis of bacterial infections remains dependent...

March 29, 2021

IBRI RESEARCH PUBLISHED: Endogenous mitochondrial double-stranded RNA is not an activator of the type I interferon response in human pancreatic beta cells

Abstract Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic beta cells. Interferon-α (IFNα), an antiviral cytokine, is expressed in the pancreatic...

March 19, 2021

IBRI IN THE NEWS: IBRI's new CEO brings experience from industry, academia

Dr. Alan Palkowitz spent 28 years in industry before becoming an academic research scientist. Those two experiences were perfect preparation for his new role as the leader of an organization...

March 08, 2021

IBRI RESEARCH PUBLISHED: Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes

Abstract The incidence of obesity and type 2 diabetes (T2D) has been increasing steadily worldwide. It is estimated that by 2045 more than 800 million people will be suffering...

February 19, 2021

IBRI RESEARCH PUBLISHED: Pro-Inflammatory Cytokines Induce Insulin and Glucagon Double Positive Human Islet Cells That Are Resistant to Apoptosis

Abstract The presence of islet cells double positive for insulin and glucagon (Ins + /Glu + ) has been described in the pancreas from both type 2 (T2D) and...

January 28, 2021

IBRI IN THE NEWS: IBRI Researchers Find Opportunity to Repurpose Drugs for Type 1 Diabetes

More than 7% of Americans suffer from debilitating and, in some cases, life-threatening autoimmune diseases. With diagnoses on the rise, researchers continue the quest for more effective treatments and the...

January 07, 2021

IBRI RESEARCH PUBLISHED: Gene Expression Signatures of Target Tissues in Type 1 Diabetes, Lupus Erythematosus, Multiple Sclerosis, and Rheumatoid Arthritis

Abstract Autoimmune diseases are typically studied with a focus on the immune system, and less attention is paid to responses of target tissues exposed to the immune assault. We...

January 06, 2021

A New Approach to Study Autoimmune Diseases

Indianapolis, Ind. - A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center’s Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for...

December 29, 2020

IBRI RESEARCH PUBLISHED: The RNA-binding Profile of the Splicing Factor SRSF6 in Immortalized Human Pancreatic ß-cells

Abstract In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. SRSF6 down-regulation promotes β-cell demise...

First 1 2 3 4 5  ... Last 
2020 Annual Report cover

The IBRI 2020 Annual Report is now available. The report theme, ‘Shaping the Future of Translational Science,’ reflects the IBRI’s commitment to turning scientific discovery into improved outcomes for patients.